ArticleBMC cardiovascular disorders2025
Prognostic significance of HANBAH score in evaluating mortality and major adverse cardiovascular events in patients with diabetes mellitus.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPredicting mortality and major adverse cardiovascular events (MACE) in Type 2 diabetes mellitus (T2DM) is important, but no routinely recommended risk score exists. The HANBAH Score is a recently established risk score for mortality prediction in acute heart failure. This study aimed to investigate the relationship between the HANBAH Score and mortality and MACE in T2DM patients.
methodsThis study was retrospective, and patients who applied to the outpatient clinic diagnosed with T2DM were included. The patients' HANBAH Score was calculated. The relationship between the HANBAH score and mortality and MACE was examined.
results7611 T2DM patients were included in this study. The mean age of the patients was 59.1 ± 12.8 years, and 3187 (41.9%) were male. The mortality rate was 1% (76 patients), and the MACE rate was 5.8% (438 patients). The mean follow-up time was 604 days. HANBAH Score was an independent predictor of mortality (HR: 2.260, 95%CI:1.738-2.939, p < 0.001) and MACE (HR: 1.238, 95%CI:1.094-1.400, p < 0.001). ROC curve analysis showed that HANBAH Score highly predicted mortality (AUC: 0.846, 95%CI: 0.794-0.898, p < 0.001).
conclusionsThis study showed that the HANBAH Score is a predictor of MACE and mortality in patients with T2DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.